This exceptional group of organizations has aligned to further efforts dedicated to the discovery, development and qualification of biological markers (i.e. biomarkers) that support new drug development, preventive medicine and medical diagnostics.
Working to support research and guide clinical practice is the main goal of The Biomarkers Consortium. This collaborative effort ensures that the voice of all stakeholders involved in biomarker research is heard and contributes to strides made in support of promising initiatives undertaken by the Consortium in areas such as Cancer, Immunity & Inflammation, Metabolic Disorders and Neuroscience.
Our current list of Contributing Members includes:
For-Profit Companies
Amgen
AstraZeneca
Crescendo Bioscience
Daiichi Sankyo, Ltd.
Eisai
Foundation for Health Improvement and Technology
Johnson & Johnson
Eli Lilly and Company
Merck, Sharpe & Dohme
Meso Scale Diagnostics
Myriad RBM
Pfizer, Inc.
Sanofi
Takeda Pharmaceuticals
Non-Profit Organizations
Alzheimer’s Association
American Diabetes Association
American Orthopaedic Society for Sports Medicine
Autism Speaks
Avon Foundation
Biotechnology Industry Organization
CHDI Foundation
Dairy Research Institute
Foundation for Health Improvement & Technology
Juvenile Diabetes Research Foundation
Pharmaceutical Research and Manufacturers of America
PROOF Centre of Excellence
Radiological Society of North America
United States Pharmacopeial Convention
Become a part of the growing list of contributing members from industry, foundations, professional associations and patient advocacy organizations, working together along with our government colleagues from the National Institutes of Health, Food and Drug Administration, and Centers for Medicare & Medicaid Services to achieve a new era of predictive, preventive and personalized medicine through biomarker research.
